Please try another search
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Lori M. Lyons-Williams | 47 | 2020 | Independent Director |
Todd R. Brady | 44 | 2019 | Independent Director |
Evert B. Schimmelpennink | 52 | 2022 | Independent Chairman of the Board |
Carmine N. Stengone | 48 | 2018 | President, CEO, Secretary & Director |
Ari Green | - | - | Clinical Advisor |
Jonah Chan | - | - | Scientific Advisor |
Elior Peles | - | - | Scientific Advisor |
Olivia C. Ware | 67 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review